行情

RMTI

RMTI

Rockwell Medical
NASDAQ

实时行情|Nasdaq Last Sale

2.600
-0.240
-8.45%
盘后: 2.930 +0.33 +12.69% 17:03 01/17 EST
开盘
2.870
昨收
2.840
最高
2.900
最低
2.600
成交量
34.60万
成交额
--
52周最高
6.88
52周最低
1.810
市值
1.66亿
市盈率(TTM)
-4.2263
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

EPS

RMTI 新闻

  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.4天前
  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.4天前
  • Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic® in India
  • GlobeNewswire.4天前
  • Rockwell Medical, Inc. Appoints Russell H. Ellison, MD, MSc, to Board of Directors
  • GlobeNewswire.01/09 22:30

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

RMTI 简况

Rockwell Medical, Inc. is a biopharmaceutical company. The Company is targeting end-stage renal disease and chronic kidney disease with products for the treatment of iron deficiency and hemodialysis. The Company is also a manufacturer of hemodialysis concentrates for dialysis providers and distributors. The Company’s renal drug therapy, Triferic, supports disease management initiatives. Triferic is therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. The Company has developed multiple formulations of Triferic: Dialysate Triferic and Intravenous Triferic (I.V. Triferic). Dialysate Triferic is the therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.
展开

Webull提供Rockwell Medical Inc的股票价格，实时市场报价，专业分析师评级，深度图表和免费的股票新闻，以帮助您做出投资决策。